Question · asked by 0 reviews
Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo): Side effects or other adverse events
- Population
- People of all ages on VKA or DOAC treatment undergoing oral or dental procedures (therapeutic INR 2.0 to 4.0; people using acetylsalicylic acid excluded)
- Intervention
- Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid)
- Comparison
- Placebo, no intervention or usual care (with or without placebo)
- Outcome
- Side effects or other adverse events
What each review found
Include earlier review versionsNo findings match. Try fewer words or remove a filter.
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions · 1 review
- Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo) · People with hemophilia (A or B) undergoing oral or dental procedures · 0 reviews
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.